Stopping GLP-1 Heart Attack Risk: What the New Study Found

The short answer

A study published in November 2026 in The Lancet Regional Health - Europe followed 80,302 adults with type 2 diabetes in Italy and found that people who stopped their GLP-1 had about 4 heart attacks, strokes or deaths per 100 people, versus about 2 per 100 among people who kept taking it. The study is observational, so it cannot prove that stopping caused the extra risk, and it mostly covered older drugs like liraglutide and dulaglutide. If you are thinking about stopping, plan it with your prescriber, and keep the habits that protect your heart and muscle. Sharpy helps with one protein target and one 20-minute workout a day.

Does stopping a GLP-1 drug raise your risk of a heart attack or stroke? A new study suggests people who stop have about twice the rate of heart attack, stroke or death compared with people who stay on, but it cannot prove the stopping itself is the cause. The study, led by Antonio Ceriello of IRCCS MultiMedica in Milan, was published in The Lancet Regional Health - Europe and reported on November 9 and 10, 2026. It followed 80,302 adults with type 2 diabetes across 301 Italian diabetes clinics.

It is the second big study this year to point the same way. Here is what each one found, what it does not show, and what to do if you are thinking about coming off.

What the new study found

The researchers looked at people with type 2 diabetes who had no known heart disease when they started a GLP-1. They followed records from 2004 to 2024 and compared people who stopped with people who kept taking their medicine.

  • About 60% of people stopped their GLP-1 at some point.
  • About 4 in 100 people who stopped had a heart attack, a stroke or died from any cause.
  • About 2 in 100 people who kept going had one of those events.
  • Looking at death from any cause alone, people who stopped were more than four times as likely to die, according to The Pharmacist.

People who stopped were more likely to be women and more likely to be on sulfonylurea pills. The study did not record why each person stopped.

Stopping GLP-1 and heart risk: the two 2026 studies side by side

Italian study (Nov 2026) US veterans study (Mar 2026)
Journal The Lancet Regional Health - Europe BMJ Medicine
People 80,302 adults with type 2 diabetes, no known heart disease 333,687 veterans with type 2 diabetes
Main drugs Mostly liraglutide and dulaglutide; few on semaglutide; no tirzepatide GLP-1s including semaglutide and tirzepatide, compared with sulfonylureas
Main finding About 4 vs 2 events per 100 people (stopped vs stayed on) Risk 14% higher after 1 year off and 22% higher after 2 years off, vs staying on
Restarting Not reported Restarting brought back some, not all, of the benefit
Design Observational Observational, built to mimic a trial

The veterans study came from Ziyad Al-Aly's team at Washington University in St. Louis. It also found that staying on a GLP-1 for three years was tied to 18% lower risk of heart attack, stroke and death than taking a sulfonylurea. People who stopped before 18 months showed no clear benefit.

Is stopping Ozempic dangerous?

Not in the sudden way that stopping some blood pressure or seizure medicines can be. The Ozempic and Wegovy labels do not list a withdrawal reaction. The concern is slower. Over months and years, what the drug was doing for your weight, blood sugar and blood pressure tends to fade. For tirzepatide, see our guide to Mounjaro withdrawal symptoms.

So the honest answer is: stopping is not an emergency, but it is a medical decision. Talk to your prescriber before you stop, and do not change your dose on your own. If cost or side effects are the reason, say so. There may be another option, a different drug or a savings program, that keeps you treated.

Why the study cannot prove stopping causes heart attacks

This is the most important part to understand. Both studies are observational. That means researchers watched what happened to people. They did not randomly assign anyone to stop.

People stop GLP-1s for reasons that can also raise heart risk on their own:

  • They lose insurance or cannot afford the drug, which often means less medical care overall.
  • They get sick with something else and stop many medicines at once.
  • Side effects like vomiting push them off, and they may already be frail.

The Italian authors wrote that stopping may be "a marker of higher underlying risk rather than a direct cause." Professor Naveed Sattar of the University of Glasgow, who was not involved, said the major limitation is that the findings are observational.

There is also a reason to think the link could be partly real. In the randomized SELECT trial (NEJM, 2023), semaglutide 2.4 mg cut heart attack, stroke and heart death by 20% in people with heart disease and overweight. If a drug lowers risk while you take it, losing it could plausibly let risk drift back up.

What happens to your body after stopping a GLP-1

The pattern from randomized trials is consistent:

What changes What the trials showed
Weight STEP 1 extension: about two thirds of lost weight came back within a year of stopping semaglutide
Weight (tirzepatide) SURMOUNT-4: people switched to placebo regained about 14% of body weight, while those who stayed on lost about 5.5% more
Appetite Hunger and food noise usually return within weeks
Blood sugar, blood pressure Gains tended to fade along with the weight

Weight that comes back after a fast loss is often more fat and less muscle than what you lost. That is one reason muscle matters so much while you are still on the drug. Our guide on resistance training on GLP-1 covers how to protect it.

Muscle you keep now is your buffer for later. Sharpy gives you one daily protein target and one 20-minute strength workout, and its Shape Score shows if you are losing fat and not muscle.

If you want to stop: questions to ask your prescriber

Bring these to your next visit:

  1. Why do I want to stop, and is there a fix for that reason (cost, side effects, supply)?
  2. Do I have heart disease, diabetes or kidney disease that this drug is helping protect?
  3. If I stop, what will replace it for blood sugar, blood pressure or cholesterol?
  4. How will we watch my weight, A1C and blood pressure in the months after?
  5. If my numbers go back up, when would we restart or switch?

Never taper, split or skip doses on your own to "come off slowly." Any change belongs in a plan you make with your prescriber. Our step-by-step guide on how to stop GLP-1 without regaining the weight walks through the lifestyle side, and the maintenance phase covers life once you hit your goal.

What this means if you have heart disease

Some GLP-1s now carry a heart indication. Wegovy is approved to lower the risk of heart attack, stroke and heart death in adults with heart disease and obesity or overweight. Read more in our guides on Mounjaro heart benefits and Wegovy and heart failure. If one of these drugs is part of your heart care, stopping it is a bigger decision, and it should be made with your cardiologist or prescriber.

The bottom line

Two large 2026 studies link stopping a GLP-1 to more heart attacks, strokes and deaths in people with type 2 diabetes. They cannot prove cause, and the newest one mostly covered older drugs. Still, the message lines up with the trials: the benefits of these drugs last while you take them. Keep the habits that protect your heart and muscle either way: enough protein, regular strength work and steady tracking. Sharpy keeps those three in one place, on the drug or off it.

Sources

Questions people ask

Does stopping a GLP-1 raise your risk of heart attack or stroke?

Two large observational studies say people who stop have higher rates. In the Italian study published in November 2026, about 4 in 100 people who stopped had a heart attack, stroke or died, versus about 2 in 100 who kept going. A March 2026 US veterans study found risk was 14% higher after one year off and 22% higher after two years off, compared with staying on. Neither study can prove stopping is the cause.

Is stopping Ozempic dangerous?

Stopping is not an emergency the way stopping some heart or seizure medicines can be. The concern from the new research is longer term: the heart benefit and the weight loss tend to fade after stopping. Do not stop on your own. Talk to your prescriber about the reason you want to stop and what would replace the drug.

Which drugs were in the new study?

Mostly liraglutide (Victoza) and dulaglutide (Trulicity). Only a small number of people used semaglutide (Ozempic), and nobody used tirzepatide (Mounjaro), according to ABC News Australia. Everyone had type 2 diabetes and no known heart disease at the start.

Why might stopping a GLP-1 be linked to more heart problems?

Researchers have two explanations. Stopping may remove a real protective effect on blood sugar, weight, blood pressure and blood vessels. Or people who stop may already be sicker, poorer or less able to keep up with care. The Italian authors said stopping may be a marker of higher risk rather than a direct cause.

What happens to your body after stopping Ozempic?

Appetite usually returns within weeks, and weight tends to come back. In the STEP 1 extension, people regained about two thirds of the weight they had lost one year after stopping semaglutide. Blood sugar, blood pressure and cholesterol improvements also tended to fade.

Does restarting a GLP-1 bring the heart benefit back?

Partly, according to the US veterans study in BMJ Medicine. People who paused and restarted kept some protection, but less than people who never stopped. Restarting, and at what dose, is a decision for your prescriber.

Read next